Transipeg 5,9 g, with its active component macrogol 3350 plus electrolytes, is commonly used to help manage symptoms related to physical discomfort and systemic imbalance associated with constipation. This formulation is applied in addressing conditions where symptoms that interfere with daily functioning become noticeable. The medicine is generally considered relevant for managing conditions involving episodic or fluctuating manifestations, and other situations involving temporary difficulty with bowel movements.

Polyethylene glycol 3350 is generally used to help with occasional constipation. This approach contributes to improved comfort during symptomatic periods, supporting patients during episodes of heightened discomfort. It is used across domains where additional symptomatic support is needed, such as in clinical scenarios involving acute or disruptive symptom patterns, where short-term symptomatic assistance is needed.

The medicine may assist with easing the overall symptom load, providing supportive relief when symptoms interfere with routine activities. As a patient-oriented benefit, this formulation helps maintain a sense of stability when symptoms are more noticeable. It is commonly used to help manage symptoms linked to organ-specific functional stress, which contributes to easing the overall symptom load.

Quick Fact: May assist with easing symptoms related to physical discomfort

Regulatory References

1. NIH MedlinePlus overview

Transipeg 5,9 g (macrogol 3350) is authorized for use in adults and the elderly. No dose adjustment is needed for patients with renal impairment.

Groups Who Must Not Use This Medicine (Contraindications)

This medicine is formally contraindicated for individuals with certain pre-existing conditions:

• Known hypersensitivity or allergy to the active substance (macrogol 3350) or any of the excipients.
• Severe inflammatory bowel conditions, such as ulcerative colitis, Crohn’s disease, or toxic megacolon.
• Any existing or suspected intestinal obstruction (ileus), symptomatic stenosis, or a perforation of the intestine or risk of perforation.
• Painful abdominal symptoms of indeterminate or unknown cause.
• Patients with phenylketonuria (due to the presence of aspartame/phenylalanine).

Specific Eligibility Considerations

Population	Eligibility Status (Regulatory)	Restriction/Precaution
Children	Not recommended under 17 years of age.	Use is not established for this age group.
Pregnancy	May be considered when necessary.	Use is considered due to negligible systemic absorption.
Lactation	May be considered when necessary.	Use is considered due to poor systemic absorption.
Hereditary Issues	Must not take.	Contraindicated in rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

Special Precautions are noted for patients on sodium- or potassium-restricted diets, as the product contains these salts, and for patients with impaired liver function who develop diarrhea.

Interactions with other medicines and products

Transipeg 5,9 g (Macrogol 3350) is characterized by a negligible level of systemic absorption. Consequently, official regulatory documentation states that pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, are not documented for the product.

Pharmacodynamic and Physicochemical Interactions

The medicine's interaction profile is instead defined by two non-systemic effects, both of which are related to its action within the gastrointestinal tract and solution chemistry.

Interaction Type	Interacting Substance/Class	Official Constraint
Pharmacodynamic	Orally administered medicinal products	May reduce absorption due to increased gastrointestinal transit.
Physicochemical	Starch-based food thickeners	Counteracts the thickening agent, resulting in a thin, watery liquid.

Administration Requirements

To mitigate the risk of reduced exposure for co-administered oral medicines, a mandatory separation in timing is recommended. Macrogol 3350 must be administered at least two hours apart from other medicinal products taken by mouth.

Population-Specific Restriction

The physicochemical interaction with starch-based thickeners presents a specific safety consideration for patients with dysphagia (swallowing difficulties). Regulatory authorities have identified that the loss of viscosity in the solution can increase the risk of aspiration in this population, and direct mixing of the products is restricted.

Osmotic Action and Water Dynamics

The mechanism of Macrogol 3350 is primarily physicochemical, as it possesses no defined biological targets such as receptors or enzymes. After ingestion, the substance, an unabsorbed polymer, acts locally within the gastrointestinal lumen. It functions as an osmotic agent, creating an osmotic gradient by binding to and retaining water molecules through hydrogen bonding. This action prevents the reabsorption of fluid from the colon back into the systemic circulation. This process results in the core physiological consequence of stool hydration and a measurable increase in its fluid content.

---

Volume-Driven Motility Modulation

This fluid retention leads to a significant increase in the fecal volume and bulk within the colon. The consequent mechanical distension of the colon wall triggers the peristaltic reflex, a spontaneous muscular contraction sequence. The increase in volume and the reflex action facilitate the propulsion and movement of the hydrated fecal mass through the large intestine, resulting in the evacuation of the bulked material.

How to Use Transipeg 5,9 g

This section describes the administration and dosage principles for Transipeg 5.9 g powder for oral solution.

---

Official Administration Guidelines

Transipeg 5.9 g is administered via the oral route after reconstitution. The typical dosing range for adults is 1 to 2 sachets daily, which provides 5.9 g to 11.8 g of Macrogol 3350.

The established frequency pattern is once daily. The total daily dose should be consumed in a single intake, preferably taken in the morning.

---

Preparation and Duration

For proper administration, the contents of one sachet must be dissolved in 100 ml of water, which is approximately one glass. The resulting solution should be consumed shortly after it is prepared.

The duration of treatment should be kept as short as possible. The medicine's effect typically becomes apparent within 24 to 48 hours after the initial administration.

---

Population-Specific Use Rules

For specific patient populations, no dose change is necessary for older adults or for patients with renal impairment. The indication for this strength is confined to use in adults.

Research evidence / Overview of Studies for Transipeg 5,9 g

---

Evidence from Core Clinical Trials: Chronic Functional Constipation

For adults with chronic functional constipation, research has primarily focused on Randomized Controlled Trials (RCTs). These studies examine outcomes related to physical discomfort and functional imbalance. Studies generally tracked changes in spontaneous bowel movement (SBM) frequency per week and monitored stool consistency using standardized scales, such as the Bristol Stool Form Scale. Systematic reviews, which combine findings from multiple trials, describe the patterns observed across studies in relation to both SBM frequency and patient-reported outcomes, such as straining or a feeling of incomplete evacuation. Findings describe patterns observed in the studies, which often lasted for short-term periods, typically one to four weeks.

---

️ Evidence for Short-Term and Occasional Use

Research exploring short-term symptom changes has involved studies where the medicine was evaluated in adults experiencing occasional or acute episodes of constipation. These trials are relevant in studies assessing short-term or episodic symptom patterns. The research explored outcomes related to the time elapsed until the first bowel movement was reported following the start of treatment. Short-term data from these settings reported measurements of symptom changes, such as the resolution of reported straining and the passage of hard stools, over very defined time intervals.

---

Research in Pediatric Populations

Specific clinical trials was studied for children, ranging across different age groups, who meet the established criteria for functional constipation. These studies included comparisons against a placebo or an active comparator such as lactulose. Research explored outcomes related to systemic or functional imbalance by tracking measures like weekly defecation frequency and stool consistency. Multiple systematic reviews of these pediatric trials reported measurements related to the evolution of symptoms in the observed populations.

---

What Is Still Uncertain: Research Gaps and Limitations

Despite the body of research, data show patterns related to certain limitations. For instance, follow-up durations were limited in many core trials, meaning there is limited information for long-term outcomes beyond one year. Evidence quality varies across studies, particularly in pediatric trials, due to a lack of standardization in how outcomes were measured and reported. Furthermore, data for certain groups remain insufficient. The results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References Polyethylene glycol 3350

Common questions about Transipeg 5,9 g (FAQ)

Q: Is Transipeg 5,9 g a generic or brand name medicine?

According to official product information, Transipeg is the brand name (or trade name) for this medicine. The active substance it contains, Macrogol 3350, is the internationally recognized generic name.

Q: What is the main ingredient in Transipeg 5,9 g?

The primary ingredient is Macrogol 3350, which is the International Nonproprietary Name for a specific form of Polyethylene Glycol (PEG). This medicine belongs to the osmotic laxative pharmacological group, which is characterized by its action of drawing and holding water in the bowel.

Q: What are the ingredients in Transipeg 5,9 g other than the active substance?

The full formulation includes excipients, which are the inactive ingredients. These include sodium and potassium salts, sucrose (sugar), and aspartame (which is a source of phenylalanine). The full list of excipients is detailed in the official product information.

Q: Is Transipeg 5,9 g the same as other polyethylene glycol products?

The active substance in Transipeg 5,9 g is Macrogol 3350, which is a specific type of polyethylene glycol (PEG). Different PEG products can vary based on their molecular weight, whether they include electrolytes, or if they have different flavoring agents in their formulation.

Q: What is the difference between Transipeg and Movicol?

Both Transipeg and Movicol contain the active substance Macrogol 3350. The key difference is often found in the other ingredients, known as excipients. Some Macrogol formulations contain a broader range of electrolytes, while others, like Transipeg, may contain a smaller amount of salts and different sweeteners.

Q: Are there different strengths of Transipeg available?

Yes, Transipeg is authorized in different strengths. The 5.9 g sachet is one variant, and other strengths, such as a 2.95 g sachet, are also authorized according to regulatory documents. The availability of different strengths is described in the regulatory authorizations.

Q: What is the difference between the 5.9 g and the 2.95 g dosage forms?

The difference between these two dosage forms is the precise amount of the active substance they contain. The 5.9 g form has 5.9 grams of Macrogol 3350, while the 2.95 g form has 2.95 grams of the same active ingredient. The availability of these dosage forms provides different amounts of the active ingredient.

Q: Why is the drug packaged in individual sachets?

The individual sachet packaging is part of the approved pharmaceutical form. This method ensures the medicine is protected from moisture and helps ensure the user takes the correct, measured dose as defined by the regulatory authorization.

Q: Is it necessary to stir the prepared solution?

Official administration guidelines indicate that the powder must be dissolved completely in water and that the resulting solution should be stirred well before being consumed.

Q: Is it necessary to mix Transipeg 5,9 g with water, or can I use another liquid?

Regulatory instructions for the preparation of this medicine specify dissolving the contents of one sachet in 100 ml of water. This is the method detailed in the official product information.

Q: What is the experience of taking Transipeg 5,9 g like (taste, texture)?

The medicine is a powder that is dissolved in water to create a liquid solution. Its specific taste is due to the flavoring agents included in the excipient list, which are approved as part of the formulation.

Q: Does Transipeg 5,9 g contain gluten or lactose?

The official excipient list for Transipeg 5,9 g confirms that the product does not contain lactose. Excipient listings indicate the medicine is free of gluten.

Q: Does Transipeg 5,9 g contain any preservatives?

The official excipient list for Transipeg 5,9 g does not list preservatives as ingredients. The short stability time of the prepared solution (24 hours) is related to this regulatory specification.

Q: Can someone with diabetes use Transipeg 5,9 g?

The medicine contains excipients such as sucrose (sugar) and aspartame (a source of phenylalanine). The product information states the need to consider the sugar content of the formulation, which is detailed in the excipient list.

Q: Does Transipeg 5,9 g have to be taken with food?

Official information indicates that the medicine can be taken without reference to food. This is a standard instruction regarding administration timing.

Q: Are there known issues with taking Transipeg 5,9 g and alcohol?

Official information states that the use of Transipeg has no known specific issues or contraindications documented with the consumption of alcohol. No specific interactions between the medicine and alcohol are documented in the official safety information.

Q: Are there known interactions between Transipeg 5,9 g and common vitamins or supplements?

The medicine may cause a transient reduction in the absorption of other orally administered products due to its action increasing the speed of transit through the gut. While the regulatory document refers to medicinal products, this physical principle may apply to other substances taken by mouth.

Q: What happens if a dose of Transipeg 5,9 g is missed?

If a dose is forgotten, official advice generally recommends taking the forgotten dose as soon as you remember, unless it is nearly time for the next scheduled dose. Official guidance includes the direction to avoid taking a double dose to compensate for a forgotten one.

Q: Does the time it takes for Transipeg 5,9 g to work vary between individuals?

The time until the effect is noticeable is described in official documents as a range of 24 to 48 hours after administration. This range accounts for the natural variation in response times that can be observed among individuals.

Q: Is there a risk of dehydration mentioned in connection with Transipeg 5,9 g?

Official safety information notes the potential for diarrhoea and electrolyte disturbances with excessive dose or inappropriate long-term use. The need to maintain adequate hydration is often noted as an important consideration when using this type of osmotic laxative.

Q: Is Transipeg 5,9 g known to affect kidney function?

Official regulatory information indicates that no dose change is necessary for the treatment of patients with renal impairment. The product information does not suggest the medicine typically affects kidney function.

Q: Why do some people refer to this type of drug as a bowel cleanser?

The term 'bowel cleanser' is an authorized description for much higher-dose formulations of Macrogol 3350, especially those combined with electrolytes. This high-dose use is regulated for preparing the colon for medical procedures, which is a different use than that for chronic constipation relief.

Q: Can Transipeg 5,9 g be taken long-term?

Administration guidelines advise that treatment duration should be kept as short as possible for symptomatic relief. However, the therapeutic indication for the active ingredient allows for long-term use in chronic conditions when the patient is under the guidance of a healthcare professional.

Q: Does Transipeg 5,9 g cause dependence if used for a long time?

The active ingredient, Macrogol 3350, acts locally in the bowel and is not absorbed into the body. Due to its physical (osmotic) mechanism and non-systemic action, the drug is not associated with dependence.

Q: Is there a maximum duration of use for Transipeg 5,9 g described in official guidelines?

Official administration guidelines state that the duration of treatment for the symptomatic relief of constipation should be kept as short as possible. No specific numerical cut-off (e.g., 7 days or 30 days) is specified for all patients.

How to Store and Dispose of Transipeg 5.9 g

The storage and handling conditions for Transipeg 5.9 g powder for oral solution are strictly defined by regulatory labeling to ensure product quality.

Storage and Stability

Product State	Storage Requirements	Shelf-Life Constraint
Unmixed Powder	Store below 25 C in the original sachet, protected from moisture.	Until labeled expiry date.
Prepared Solution	Store refrigerated, between 2 C and 8 C.	Must be used within 24 hours of reconstitution.

️ Safety and Disposal

All unopened powder sachets must be stored out of the sight and reach of children. To dispose of any unused or expired Transipeg, the product information requires following local regulatory guidelines for pharmaceutical waste.